Table 1.
Basic characteristics of the study participants
| Characteristics | Total |
|---|---|
| Age | 50(43–55) |
| Current smoking, N (%) | 1(1) |
| Hormone receptor status, N (%) | |
| ER+ | 89(60) |
| ER + PR+ | 83(56) |
| ER + PR- | 5(3) |
| ER-PR- | 35(23) |
| HER2+ | 12(8) |
| ER-PR-HER2- | 18(12) |
| Family history of breast cancer, N (%) | 25(17) |
| Post-menopausal, N (%) | 111(76) |
| Hormone therapy for breast cancer | 112(76) |
| Stage, N (%) | |
| Stage I | 33(22) |
| Stage II | 61(41) |
| Stage III | 35(24) |
| Missing | 18(13) |
| Recurrence N (%) | |
| Yes | 5(3) |
| No | 77(67) |
| Unknown | 65(30) |
| Physical activity levels, N (%) | |
| Low physical activity | 80(54) |
| Moderate physical activity | 44(30) |
| High physical activity | 23(16) |
| Energy intake, Kcal | 1901(1832–2046) |
| Fat intake, grams | 84 ± 16 |
| Protein intake, grams | 56(49–62) |
| Carbohydrate intake, grams | 243 ± 41 |
| Pre intervention Vitamin D, nmol/liter | 38(22–62) |
| Post intervention vitamin D, nmol/liter | 110 ± 46 |
| ApaI N (%) | |
| AA | 68(49) |
| Aa | 52(38) |
| aa | 18(13) |
| TaqI N (%) | |
| TT | 57(41) |
| Tt | 67(49) |
| tt | 14(10) |
| BsmI N (%) | |
| BB | 66(45) |
| Bb | 65(44) |
| bb | 16(11) |
| FokI N (%) | |
| FF | 64(44) |
| Ff | 66(45) |
| ff | 17(12) |
| Cdx2 N (%) | |
| GG | 81(55) |
| AG | 52(35) |
| AA | 14(10) |
ER Estrogen Receptor, PR Progesterone Receptor, HER2 Human Epidermal Growth Factor Receptor 2, BMI Body Mass Index, BMI Body Mass Index, WC Waist Circumference, HC Hip Circumference
Values with normal distribution are presented as mean ± SD, values with non-normal distribution as median (Q1, Q3) and categorical variables as N (%)